SYS-CON MEDIA Authors: Mark R. Hinkle, Glenn Rossman, Kevin Benedict, Jason Bloomberg, Unitiv Blog

News Feed Item

Hapten Sciences, Inc. and Particle Sciences, Inc. Partner to Bring Hapten's Poison Ivy Product Into Clinical Trials

BETHLEHEM, Pa., Jan. 28, 2014 /PRNewswire/ -- Particle Sciences, Inc. a drug delivery Contract Development and Manufacturing Organization (CDMO), has partnered with Hapten Sciences, Inc. to progress Hapten's lead product into the clinic. The product is a vaccine developed to lessen or eliminate contact dermatitis from Poison Ivy, Oak and Sumac exposure. According to Raymond Hage, CEO of Hapten, "Experts report that 50 to 85 percent of the population in the United States is sensitive to urushiol and, when adequately exposed, will suffer an allergic reaction. Aside from the actual physical discomfort, these reactions cost the federal government and private business millions each year in lost workdays. For instance, in the western US, annually, about one third of US Forest Service Firefighters will leave a fire as a result of exposure to Poison Ivy, Oak or Sumac." Particle Sciences will be manufacturing the Phase I/II materials of Hapten's first human studies scheduled for 2014. According to Mark Mitchnick, MD, Particle Sciences' CEO, "We have worked with Hapten in the past and are delighted to be helping them bring this important product to market. This a great use of our sterile solution manufacturing capacity: producing and filling a novel product along with providing complete analytic (service info) and release testing (service info).  We have steadily expanded or cGMP manufacturing capacity with a focus on sterile and otherwise challenging products and have several in the queue already for early 2014."

Particle Sciences, Inc. is an integrated pharmaceutical CDMO.  Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email [email protected] or contact us at (610) 861-4701 for information.

Hapten Sciences, Inc. is a privately held biopharmaceutical company based in Memphis, Tennessee. The company's mission is to identify and efficiently develop novel, early-stage products that will significantly contribute to the health and well-being of people around the world.  The company's initial product is a small molecule that acts like a vaccine to prevent the extremely painful itching and rash (contact dermatitis) caused by exposure to urushiol (yoo-ROO-she-ol) oil in poison ivy, poison oak and poison sumac plants. The development of the this product is progressing and Hapten intends to begin clinical trials this year.

Contact:
Maureen Grieco
[email protected] 

SOURCE Particle Sciences, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.